drugset / Trial / NCT00717145

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

NCT00717145

Phase 1 Completed 94 enrolled Warner Chilcott Sanofi · collab
RandomizedCrossoverOpen-label

Summary

Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment period), and exit procedures.

Timeline

Start
2008-07
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 20 mg
Subject Risedronate Small molecule 35 mg

Indications

No indication recorded.